Study aim: Effect of aqueous extarct of licorice in coronavirus outpatients Design: Randomized, blinded, placebo controlled clinical trial. Effect of licorice capsules in 20 patients which have inclusion criteria will be evaluated. Simultanously, 20 patients will take placebo. Medicine and placebo in the same form and package with the alphabetics A and B will be deliverd to physiciana and patients. Patients must take the capsules three times a day for 14 days Settings and conduct: Randomized, blinded, placebo controlled clinical trial will be in mashhad . effect of licorice capsules in 20 patients with coronavirus disease which have inclusion criteria will be evaluated. Simultanously 20 patients will take placebo. Medicine and placebo in the same form and package with the alphabetics A and B will be deliverd to physician and patients. The patients must take the capsules three times a day for 14 days Participants/Inclusion and exclusion criteria: Inclusion criteria: The outpatients in quarantine, take medicine, diagnosed for coronavirus disease according to clinic ( fever, cough, myalgia) and paraclinic parameters (lymphopenia, increase CRP). Exclusion criteria: Sensitivity to licorice and it derivatives; below 18 and above 65 years old; hepato, renal or respiratory disorders; take cytotoxic, corticosteroid drugs; nursing or pregnant women Intervention groups: Effect of licorice capsules in 20 patients which have inclusion criteria will be evaluated. Simultanously 20 patients which have inclusion criteria will take placebo. Main outcome variables: Time interval until lymphopenia improves Time interval until CRP normalizes Time interval until clinical symptoms improve (fever, cough and myalgia)